- The newer insulins have greater similarity to each other than to the older insulins
|
- The newer short acing insulins may enable more flexibility with dosing regimens, meal composition and requirement for between meal snacks than older insulins
|
- Both detemir and glargine may need to be used in a twice daily regimen to enable control of HbA1c
|
- Detemir may have weight advantages over older insulins in obese people with type 2 diabetes
|
- Older insulins have a wealth of safety data and as yet the mitogenic potential of the new insulins, especially over a lifetime is not fully known
|
- Newer insulins do not provide any efficacy advantage (in terms of HbA1c) but do offer convenience and may provide a reduction (but not elimination) of nocturnal hypoglycaemia
|
